Targeting histone modifiers in bladder cancer therapy — preclinical and clinical evidence
- 19 February 2024
- journal article
- review article
- Published by Springer Nature in Nature Reviews Urology
- Vol. 21 (8) , 495-511
Abstract
Bladder cancer in the most advanced, muscle-invasive stage is lethal, and very limited therapeutic advances have been reported for decades. To date, cisplatin-based chemotherapy remains the first-line therapy for advanced bladder cancer. Late-line options have historically been limited. In the past few years, next-generation sequencing technology has enabled chromatin remodelling gene mutations to be characterized, showing that these alterations are more frequent in urothelial bladder carcinoma than in other cancer types. Histone modifiers have functional roles in tumour progression by modulating the expression of tumour suppressors and oncogenes and, therefore, have been considered as novel drug targets for cancer therapy. The roles of epigenetic reprogramming through histone modifications have been increasingly studied in bladder cancer, and the therapeutic efficacy of targeting those histone modifiers genetically or chemically is being assessed in preclinical studies. Results from preclinical studies in bladder cancer encouraged the investigation of some of these drugs in clinical trials, which yield mixed results. Further understanding of how alterations of histone modification mechanistically contribute to bladder cancer progression, drug resistance and tumour microenvironment remodelling will be required to facilitate clinical application of epigenetic drugs in bladder cancer.Keywords
This publication has 158 references indexed in Scilit:
- KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis InhibitionAdvanced Science, 2023
- Bladder CancerJAMA, 2020
- Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genesCancer, 2018
- Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma modelCancer Immunology, Immunotherapy, 2018
- Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancerInternational Journal of Cancer, 2018
- The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapyCancer Immunology, Immunotherapy, 2017
- The JmjC domain‐containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 geneInternational Journal of Cancer, 2011
- Role of androgen receptor and associated lysine‐demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancerMolecular Carcinogenesis, 2011
- Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancersInternational Journal of Cancer, 2010
- SET domain proteins modulate chromatin domains in eu- and heterochromatinCellular and Molecular Life Sciences, 1998